Coupling Bio-Resonance Neurotechnology (BRNT) and Dual Hemispheric Repetitive Transcranial Magnetic Stimulation (rTMS) Reduces Comorbid Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) as Demonstrated by PHQ-9 and GAD-7: Pilot Case Series
Keerthy Sunder,1– 3,* Milan T Makale,4,* Miles Makale,5,* Jothsna Bodhanapati,2,* Kevin T Murphy,6,* Catherine A Dennen,7,* David Baron,8,* Panayotis K Thanos,9,10,* Colin Hanna,9,* John Wesson Ashford Jnr,11,* Kai-Uwe L...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-02-01
|
| Series: | Psychology Research and Behavior Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/coupling-bio-resonance-neurotechnology-brnt-and-dual-hemispheric-repet-peer-reviewed-fulltext-article-PRBM |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Keerthy Sunder,1– 3,* Milan T Makale,4,* Miles Makale,5,* Jothsna Bodhanapati,2,* Kevin T Murphy,6,* Catherine A Dennen,7,* David Baron,8,* Panayotis K Thanos,9,10,* Colin Hanna,9,* John Wesson Ashford Jnr,11,* Kai-Uwe Lewandrowski,12,* Kenneth Blum3,8,10,* 1Department of Psychiatry, University California, UC Riverside School of Medicine, Riverside, CA, USA; 2Division of Neuromodulation Research, Karma Doctors & Karma TMS, Palm Springs, CA, USA; 3Sunder Foundation, Palm Springs, CA, USA; 4Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA; 5Department of Psychology, University of California San Diego, San Diego, CA, USA; 6PeakLogic Inc., Del Mar, CA, USA; 7Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA; 8Division of Addiction Research & Education, Center for Sports, Exercise and Mental Health, Western University Health Sciences, Pomona, CA, USA; 9Behavioral Neuropharmacology and Neuroimaging Laboratory On Addictions (BNNLA), Research Institute On Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; 10Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel; 11Stanford University, Psychiatric /Public Mental Health & Population Sciences Palo Alto, Stanford, CA, USA; 12Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá D.C., Colombia*These authors contributed equally to this workCorrespondence: Kenneth Blum, Email drd2gene@gmail.comAbstract: Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) are prevalent comorbidities related to a greater likelihood of poor treatment outcomes and prolonged treatment for Reward Deficiency Syndrome (RDS) behaviors. The current exploratory case study of a small cohort (n=3; f=2 m=1) used novel neurotechnology to treat co-occurring MDD and GAD with a multifaceted intervention that combines the novel bio-resonance neurotechnology (BRNT) referred to as NuCalm®, to restore autonomic nervous system balance and dual hemispheric repetitive transcranial magnetic stimulation (rTMS) of the ipsilateral Dorsal Lateral Prefrontal Cortex (DLPFC) to treat the disrupted structural components of the brain. Neuroacoustic brainwave entrainment, electromagnetic frequency bio-resonance, and light-blocking combine to place patients into a parasympathetic dominant state. The paired t-tests indicated a significant decrease in comparing before and after the intervention. The Patient Health Questionnaire PHQ-9 scores from the first to the last time-point (mean difference = 20, t(2) = 6.55, p = 0.0226), with a 95% confidence interval of mean difference ranging from 6.86 to 33.14. Similarly, there was a significant decrease in General Anxiety Disorder GAD-7 questionnaire scores from the first to the last time point (mean difference = 18.67, t(2) = 12.85, p = 0.0060), with a 95% confidence interval of the mean difference ranging from 12.42 to 24.92. After applying the Bonferroni correction, the corrected p-values for PHQ-9 and GAD-7 are 0.0452 and 0.0120, respectively. Cohen’s d standardized effect size indicated that the main effect size was 5.47 and 13.8 times the noise (variability), respectively, for the initial versus final PHQ-9 and GAD-7. Further, more extensive, much larger sham-controlled and blinded studies are required to confirm these encouraging results and explore this multifaceted intervention.Keywords: reward deficiency syndrome(RDS), RDS, parasympathetic and sympathetic nervous systems, repetitive transcranial magnetic stimulation(rTMS), rTMS, novel bio-résonance neurotechnology |
|---|---|
| ISSN: | 1179-1578 |